Toll Like Receptor 4 hToll or CD284 or TLR4 Pipeline Review, H2 2017 [Report Updated: 25072017] Prices from USD $3500
Toll Like Receptor 4 hToll or CD284 or TLR4 Pipeline Review, H2 2017
Summary
Toll Like Receptor 4 hToll or CD284 or TLR4 Tolllike receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPSindependent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require nonconserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized lowdensity lipoprotein oxLDL.
Toll Like Receptor 4 hToll or CD284 or TLR4 pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 3, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Pulmonary Inflammation, Breast Cancer, Inflammation, Inflammatory Bowel Disease, Liver Fibrosis, NonAlcoholic Steatohepatitis NASH, Atherosclerosis, Autoimmune Hepatitis, Drug Addiction, Kidney Disease, Kidney Fibrosis, Rheumatoid Arthritis, Sepsis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acne Vulgaris, Acute Ischemic Stroke, Acute Lung Injury, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Crohn's Disease Regional Enteritis, Ebolavirus Infections Ebola Hemorrhagic Fever, Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy Krabbe Disease, Hearing Disorders, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Human Immunodeficiency Virus HIV Infections AIDS, Human Papillomavirus HPV Associated Cancer, Human Papillomavirus Infections, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca Dry Eye, Leishmaniasis KalaAzar, Listeriosis, Lung Cancer, Marburgvirus Infections Marburg Hemorrhagic Fever, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease NAFLD, Non Muscle Invasive Bladder Cancer NMIBC Superficial Bladder Cancer, NonHodgkin Lymphoma, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, PostTraumatic Stress Disorder PTSD, Primary Progressive Multiple Sclerosis PPMS, Prostate Cancer, Pseudomonas aeruginosa Infections, Recurrent Glioblastoma Multiforme GBM, Rosacea, Secondary Progressive Multiple Sclerosis SPMS, Septic Shock, Trauma, Wounds, Xerostomia and Zika Virus Infections.
The latest report Toll Like Receptor 4 Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 hToll or CD284 or TLR4
The report reviews Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics and enlists all their major and minor projects
The report assesses Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 hToll or CD284 or TLR4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 hToll or CD284 or TLR4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Toll Like Receptor 4 hToll or CD284 or TLR4 Pipeline Review, H2 2017 [Report Updated: 25072017] Prices from USD $3500
